Inactive Instrument
Five Prime Therapeutics, Inc. Share Price
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 16/04/21 | Issuer sale | Director | 46,250 | 0.0993% | ||
| 16/04/21 | Issuer sale | Director | 60,000 | 0.1288% | ||
| 16/04/21 | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| +0.93% | +6.97% | +59.60% | +68.35% | 57.28B | |
| -1.92% | +6.03% | +40.64% | +83.42% | 54.99B | |
| -0.46% | -1.29% | +2.86% | +428.78% | 23.18B | |
| -2.97% | -2.35% | -22.53% | -16.40% | 22.59B | |
| -0.36% | +5.73% | +24.13% | -6.24% | 20.46B | |
| -1.34% | +0.51% | +26.03% | -29.41% | 17.56B | |
| -1.44% | +5.67% | +38.77% | +504.71% | 15.67B | |
| -1.30% | -5.02% | +170.77% | +291.37% | 14.46B | |
| -0.50% | -0.98% | +21.43% | +180.07% | 13.92B | |
| Average | -0.93% | +1.28% | +40.19% | +167.18% | 26.68B | |
| Weighted average by Cap. | -0.87% | +2.10% | +39.70% | +133.49% |
Employees
51
